Skip to main content
SpringerLink
Log in

Reducing costs of HCV-related liver disease

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. reported in 2013 US dollars

Reference

  • Sievert W, et al. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. Journal of Gastroenterology and Hepatology 29 (Suppl. 1): 1-9, Aug 2014. Available from: URL: http://doi.org/10.1111/jgh.12677

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reducing costs of HCV-related liver disease. PharmacoEcon Outcomes News 709, 7 (2014). https://doi.org/10.1007/s40274-014-1460-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1460-4

Search

Navigation